ADVERTISEMENT
French virology company Abivac will receive €390,000 for the development of a polyclonal antibody cocktail to fight Ebola.
Antibody and sample diluent for minimizing nonspecific binding, cross-reactivities and matrix effects in immunoassays.
Orphan diseases diagnostics specialist Centogene AG said it will use the funds for biomarker and CDx development based on its proprietary CentoMD mutation database.
Swedish orthobiologics company Bonesupport Holding AB announced on Sunday it will go public at Nasdaq Stockholm.
Norwegian cancer med developer Targovax ASA has doubled its cash and cash equivalents as of 31 December 2016 by raising NOK200m (€21m) in a private placement of new shares.
German Grünenthal Group has entered into an agreement to acquire the global rights to AstraZenecas migraine treatment Zolmitriptan.
Belgian liquid biopsy specialist Biocartis Group NV has announced it will co-develop a breast cancer assay with MRC Technology.